RBC Capital Believes Charles River Labs (CRL) Won’t Stop Here


In a report released yesterday, George Hill from RBC Capital reiterated a Buy rating on Charles River Labs (CRL), with a price target of $147. The company’s shares closed yesterday at $136.23, close to its 52-week high of $138.89.

According to TipRanks.com, Hill is a 2-star analyst with an average return of 0.0% and a 45.0% success rate. Hill covers the Services sector, focusing on stocks such as AmerisourceBergen Corporation, Walgreens Boots Alliance, and Cardinal Health.

Currently, the analyst consensus on Charles River Labs is a Hold with an average price target of $133.50, a -2.0% downside from current levels. In a report released yesterday, Robert W. Baird also maintained a Buy rating on the stock with a $148 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $138.89 and a one-year low of $96.70. Currently, Charles River Labs has an average volume of 364.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts